Literature DB >> 12458683

Complexation of VEGF with bevacizumab decreases VEGF clearance in rats.

Vanessa Hsei1, Geralyn G Deguzman, Alison Nixon, Jacques Gaudreault.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12458683     DOI： 10.1023/a:1020778001267

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.200


× No keyword cloud information.
  13 in total

1.  Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

Authors:  H Milgrom; R B Fick; J Q Su; J D Reimann; R K Bush; M L Watrous; W J Metzger
Journal:  N Engl J Med       Date:  1999-12-23       Impact factor: 91.245

2.  What is the evidence that tumors are angiogenesis dependent?

Authors:  J Folkman
Journal:  J Natl Cancer Inst       Date:  1990-01-03       Impact factor: 13.506

3.  Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.

Authors:  Y S Lin; C Nguyen; J L Mendoza; E Escandon; D Fei; Y G Meng; N B Modi
Journal:  J Pharmacol Exp Ther       Date:  1999-01       Impact factor: 4.030

4.  Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys.

Authors:  J A Fox; T E Hotaling; C Struble; J Ruppel; D J Bates; M B Schoenhoff
Journal:  J Pharmacol Exp Ther       Date:  1996-11       Impact factor: 4.030

Review 5.  The biology of vascular endothelial growth factor.

Authors:  N Ferrara; T Davis-Smyth
Journal:  Endocr Rev       Date:  1997-02       Impact factor: 19.871

6.  Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.

Authors:  M S Gordon; K Margolin; M Talpaz; G W Sledge; E Holmgren; R Benjamin; S Stalter; S Shak; D Adelman
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

7.  Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.

Authors:  H P Gerber; J Kowalski; D Sherman; D A Eberhard; N Ferrara
Journal:  Cancer Res       Date:  2000-11-15       Impact factor: 12.701

8.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.

Authors:  L G Presta; H Chen; S J O'Connor; V Chisholm; Y G Meng; L Krummen; M Winkler; N Ferrara
Journal:  Cancer Res       Date:  1997-10-15       Impact factor: 12.701

9.  Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE.

Authors:  J Liu; P Lester; S Builder; S J Shire
Journal:  Biochemistry       Date:  1995-08-22       Impact factor: 3.162

10.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.

Authors:  K J Kim; B Li; J Winer; M Armanini; N Gillett; H S Phillips; N Ferrara
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962
View more
  20 in total

Review 1.  Application of quantitative pharmacology in development of therapeutic monoclonal antibodies.

Authors:  Mohammad Tabrizi; Cherryl Funelas; Hamza Suria
Journal:  AAPS J       Date:  2010-07-24       Impact factor: 4.009

Review 2.  Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer.

Authors:  Katherine F Croom; Sohita Dhillon
Journal:  Drugs       Date:  2011-11-12       Impact factor: 9.546

3.  The effect of bevacizumab on colon anastomotic healing in rats.

Authors:  Efstathios T Pavlidis; Konstantinos D Ballas; Nikolaos G Symeonidis; Kyriakos Psarras; Georgios Koliakos; Kokona Kouzi-Koliakos; Konstantina Topouridou; Savas F Rafailidis; Theodoros E Pavlidis; Georgios N Marakis; Athanasios K Sakantamis
Journal:  Int J Colorectal Dis       Date:  2010-08-06       Impact factor: 2.571

4.  Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity.

Authors:  Madelon Q Wentink; Tilman M Hackeng; Sebastien P Tabruyn; Wouter C Puijk; Klaus Schwamborn; Daniele Altschuh; Rob H Meloen; Teun Schuurman; Arjan W Griffioen; Peter Timmerman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-17       Impact factor: 11.205

5.  Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model.

Authors:  Marianne O Stefanini; Florence T H Wu; Feilim Mac Gabhann; Aleksander S Popel
Journal:  Cancer Res       Date:  2010-11-30       Impact factor: 12.701

Review 6.  Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research.

Authors:  Y Zhang; S Doshi; M Zhu
Journal:  Br J Clin Pharmacol       Date:  2015-05-26       Impact factor: 4.335

7.  Endothelial cell capture of heparin-binding growth factors under flow.

Authors:  Bing Zhao; Changjiang Zhang; Kimberly Forsten-Williams; Jun Zhang; Michael Fannon
Journal:  PLoS Comput Biol       Date:  2010-10-28       Impact factor: 4.475

Review 8.  Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review.

Authors:  Susan E Pories; Gerburg M Wulf
Journal:  Breast Cancer (Dove Med Press)       Date:  2010-06-21

9.  Quantitative analysis of target coverage and germinal center response by a CXCL13 neutralizing antibody in a T-dependent mouse immunization model.

Authors:  Joanne Brodfuehrer; Andrew Rankin; Jason Edmonds; Sean Keegan; Tatyana Andreyeva; Rosemary Lawrence-Henderson; Josef Ozer; Huilan Gao; Laird Bloom; Angela Boisvert; Khetemenee Lam; Julie Lee; Timothy LaBranche; Jameel Syed; Wenyan Miao; Pratap Singh
Journal:  Pharm Res       Date:  2013-11-05       Impact factor: 4.200

10.  Diffusion-weighted MR imaging in liver metastases of colorectal cancer: reproducibility and biological validation.

Authors:  Linda Heijmen; Edwin E G W Ter Voert; Iris D Nagtegaal; Paul Span; Johan Bussink; Cornelis J A Punt; Johannes H W de Wilt; Fred C G J Sweep; Arend Heerschap; Hanneke W M van Laarhoven
Journal:  Eur Radiol       Date:  2012-09-23       Impact factor: 5.315
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.